logo
Nuclear fusion start-up claims to have cracked alchemy

Nuclear fusion start-up claims to have cracked alchemy

Telegraph22-07-2025
Over thousands of years, it has captivated thinkers such as Newton, the English physicist who developed the mathematical law of universal gravitation in the late 17th century.
Many dreamed of creating a 'philosopher's stone' that would be used as a catalyst for transmuting base metals such as lead into gold.
Marathon's idea relies on substituting materials used in the well-understood process of nuclear fusion instead.
Fusion takes place when two isotopes of hydrogen, deuterium and tritium, are forced together to create helium, releasing high-energy subatomic particles called neutrons.
It is accomplished by heating the deuterium and tritium atoms to extreme temperatures of more than 100 million degrees Celsius and then confining them into a tight space so that they collide.
The process becomes self-sustaining when helium atoms collide with the fuel particles, transferring their energy and ensuring the reaction keeps going.
But fusion reactors typically contain other materials, including isotopes of beryllium, lead, or lithium, to ensure there is continuously enough tritium in the mix.
These are known as 'multipliers' because when they are hit by a neutron, they release two neutrons in their place. These extra neutrons then react with lithium to produce tritium.
Radical transformation
Marathon's method uses mercury-198, a common form of mercury, as a multiplier. When hit by a neutron, these atoms change into a less stable form called mercury-197.
Over a few days, those atoms then naturally break down into a stable form of gold.
Marathon claims this means the fusion process can be used to generate supplies of gold as a byproduct, 'without any compromise to fuel self-sufficiency or power output'.
Using the new approach, the company says a fusion power plant with a capacity of about one gigawatt could generate 5,000 kilograms of gold per year.
The gold produced by the reaction is stable, but could contain some radioactive gold isotopes, potentially meaning it must be stored for up to 18 years, according to the company.
The start-up added: 'Marathon's techno-economic modelling suggests that fusion plants could create as much economic value from gold production as they do from electricity production, potentially doubling the value of these facilities, radically transforming the economics of fusion and of energy more broadly.'
Beyond gold, it also claimed the transmutation process could be used for making precious metals such as palladium, synthesising medical isotopes, or producing materials for 'nuclear batteries'.
Marathon was founded by Adam Rutkowski, a former engineer at Elon Musk's rocket company, SpaceX, and Kyle Schiller, who was a fellow at ex-Google boss Eric Schmidt
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

CureVac settles mRNA patent dispute litigation with Pfizer and BioNTech
CureVac settles mRNA patent dispute litigation with Pfizer and BioNTech

Reuters

timean hour ago

  • Reuters

CureVac settles mRNA patent dispute litigation with Pfizer and BioNTech

Aug 7 (Reuters) - German drugmaker CureVac ( opens new tab and GSK (GSK.L), opens new tab reached an agreement with BioNTech ( opens new tab and Pfizer (PFE.N), opens new tab on Thursday to resolve a years-long patent dispute related to mRNA-based COVID-19 vaccines, CureVac said. As part of the settlement, CureVac and GSK will receive a combined payment of $740 million and single-digit royalties on sales of COVID-19 vaccines in the U.S. going forward. CureVac will also grant BioNTech and Pfizer a non-exclusive license to manufacture, use, import and sell mRNA-based COVID-19 and influenza products in the U.S. The settlement comes after BioNTech agreed to acquire its domestic peer CureVac in a $1.25 billion all-stock deal in June. Three years ago, CureVac had filed a patent lawsuit against BioNTech over its use of mRNA technology, seeking fair compensation from the company and two of its subsidiaries for infringement of its intellectual property rights. CureVac had said that its claim to intellectual property rights was based on more than two decades of work on mRNA technology, some of which was used by BioNTech and Pfizer for the development and sale of their Comirnaty coronavirus vaccine. CureVac's efforts to develop an mRNA-based COVID-19 vaccine did not come to fruition during the pandemic, whereas BioNTech and its partner Pfizer chalked up more than $40 billion in combined vaccine sales in 2021 and 2022.

Butterfly from Southern Europe spotted in UK for first time
Butterfly from Southern Europe spotted in UK for first time

BBC News

timean hour ago

  • BBC News

Butterfly from Southern Europe spotted in UK for first time

A species of butterfly previously only found in Southern Europe has been seen in the UK for the first time, according to charity Butterfly have tracked the Southern Small White butterfly's rapid expansion northwards through Europe over recent first UK sighting was confirmed at Landguard Bird Observatory in Suffolk, after a volunteer managed to snap a is not yet clear what has driven the species' expansion, though a warming climate is thought to be part of the answer. Until recently, the range of the Southern Small White was limited to Southern Europe, in particular south-east Conservation says the species was first spotted north of the Alps in France and Germany in 2008, and since then it has gradually extended its range, reaching the Netherlands in 2015 and Calais in first UK visitor was a female butterfly and was spotted at Landguard Nature Reserve on 2 August by volunteer Will Brame, according to BirdGuides. Its identification as a Southern Small White was confirmed by butterfly expert Chris van Swaay of Dutch Butterfly Corton, a County Recorder for Butterflies in Suffolk, contacted us about the story through Your Voice, Your BBC it is thought a warming climate has played a role in its spread, modelling from a 2008 Climatic Risk Atlas of European Butterflies showed that even under the most extreme warming scenarios the species was not expected in the Low Countries until after 2050. Dr Dan Hoare, Director of Nature Recovery at Butterfly Conservation, said the species had made an "ecological leap"."There are species that are rare in the UK and periodically over the years they have turned up in ones and twos... but it's not really indicating any significant shift in our fauna," he said."Southern Small White is very different. It's basically colonised northern Europe from the Swiss Alps to the North Sea in the last decade, moving north at a rate of about 100 kilometres [62 miles] a year."But whether the species stays long term is yet to be seen, he says, as its food source is a garden species called Candytuft that is not as widely planted species has never been a migrant to the UK, and is yet to have been recorded breeding here, which is what a resident species would do.

CureVac settles patent dispute litigation with Pfizer and BioNTech
CureVac settles patent dispute litigation with Pfizer and BioNTech

Reuters

timean hour ago

  • Reuters

CureVac settles patent dispute litigation with Pfizer and BioNTech

Aug 7 (Reuters) - CureVac ( opens new tab said on Thursday that the company and GSK (GSK.L), opens new tab have entered an agreement to a resolve patent dispute with Pfizer (PFE.N), opens new tab and BioNTech ( opens new tab related to mRNA-based COVID-19 vaccines. As part of the settlement, CureVac and GSK will receive a combined payment of $740 million and single-digit royalties on sales of COVID-19 vaccines in the U.S. going forward. CureVac will also grant BioNTech and Pfizer a non-exclusive license to manufacture, use, import and sell mRNA-based COVID-19 and influenza products in the U.S.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store